Narukawa M - Search Results

1

Analysis of Pediatric Drug Approval Lag in Japan.

Ueyama E, Kaneko M, Narukawa M. Ueyama E, et al. Among authors: narukawa m. Ther Innov Regul Sci. 2021 Mar;55(2):336-345. doi: 10.1007/s43441-020-00218-z. Epub 2020 Sep 21. Ther Innov Regul Sci. 2021. PMID: 32959206

2

Differences between Japan and the United States in dosages of drugs recently approved in Japan.

Nakashima K, Narukawa M, Kanazu Y, Takeuchi M. Nakashima K, et al. Among authors: narukawa m. J Clin Pharmacol. 2011 Apr;51(4):549-60. doi: 10.1177/0091270010375958. Epub 2010 Jul 13. J Clin Pharmacol. 2011. PMID: 20628171

3

Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.

Nakashima K, Narukawa M, Takeuchi M. Nakashima K, et al. Among authors: narukawa m. Clin Pharmacol Ther. 2011 Dec;90(6):836-43. doi: 10.1038/clpt.2011.156. Epub 2011 Nov 2. Clin Pharmacol Ther. 2011. PMID: 22048222

4

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer.

Aboshi M, Kaneko M, Narukawa M. Aboshi M, et al. Among authors: narukawa m. J Cancer Res Clin Oncol. 2014 May;140(5):839-48. doi: 10.1007/s00432-014-1617-3. Epub 2014 Feb 22. J Cancer Res Clin Oncol. 2014. PMID: 24562618 Free PMC article.

5

An investigation of factors contributing to higher levels of placebo response in clinical trials in neuropathic pain: a systematic review and meta-analysis.

Arakawa A, Kaneko M, Narukawa M. Arakawa A, et al. Among authors: narukawa m. Clin Drug Investig. 2015 Feb;35(2):67-81. doi: 10.1007/s40261-014-0259-1. Clin Drug Investig. 2015. PMID: 25559268 Review.

6

Investigation of prognostic factors affecting efficacy in carboplatin- and paclitaxel-based first-line chemotherapies for advanced non-small-cell lung cancer.

Komuro M, Kaneko M, Narukawa M. Komuro M, et al. Among authors: narukawa m. Tumori. 2015 Jul-Aug;101(4):424-32. doi: 10.5301/tj.5000333. Epub 2015 Apr 22. Tumori. 2015. PMID: 25908047

7

Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.

Murakami M, Narukawa M. Murakami M, et al. Among authors: narukawa m. Drug Discov Today. 2016 Apr;21(4):544-9. doi: 10.1016/j.drudis.2016.02.016. Epub 2016 Mar 2. Drug Discov Today. 2016. PMID: 26945941 Review.

8

Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.

Kaneko M, Narukawa M. Kaneko M, et al. Among authors: narukawa m. Diabetes Res Clin Pract. 2016 Jun;116:171-82. doi: 10.1016/j.diabres.2016.04.012. Epub 2016 Apr 27. Diabetes Res Clin Pract. 2016. PMID: 27321333

9

Potential Primary Endpoint for Exploratory Clinical Trial in Patients with Overactive Bladder: A Systematic Literature Review.

Iino S, Kaneko M, Narukawa M. Iino S, et al. Among authors: narukawa m. Low Urin Tract Symptoms. 2018 Jan;10(1):64-75. doi: 10.1111/luts.12141. Epub 2016 Oct 28. Low Urin Tract Symptoms. 2018. PMID: 27792298

10

Fujita K, Kaneko M, Narukawa M. Fujita K, et al. Among authors: narukawa m. Clin Drug Investig. 2017 Mar;37(3):219-232. doi: 10.1007/s40261-016-0478-8. Clin Drug Investig. 2017. PMID: 27848150 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

193 results

Search Page

Filters